Sinclair Pharma

Executive Summary

Sinclair Pharma, a global medical aesthetics company headquartered in Paris and founded in 1971, operates as a wholly-owned subsidiary of Huadong Medicine Co., Ltd. of China. The company develops, manufactures, and commercializes a broad portfolio of injectable products (e.g., dermal fillers, botulinum toxin) and energy-based devices for holistic aesthetic treatments. Leveraging Huadong's resources and distribution network, Sinclair has a strong presence in China and international markets, focusing on high-growth segments like minimally invasive procedures. While privately held and not publicly traded, Sinclair's performance is consolidated into Huadong's financials, making it a key contributor to the parent's aesthetics division.

Upcoming Catalysts (preview)

• Q3 2026New product launch in China (e.g., next-generation hyaluronic acid filler)70% success
• Q4 2026FDA or CE approval for a novel energy-based device50% success
• Q2 2026Expansion of sales force or distribution partnerships in Asia-Pacific80% success